Pharmacological NRF2-activators have routinely proven to reverse disease-like phenotypes in models of almost all aspects of cardiovascular disorders [6] including heart failure [7,8], myocardial infarction [9], cardiomyopathies [8,10], atherosclerosis [11] and fibrosis [12,13]. This evidence concerns the gene NFE2L2 and cardiovascular disorder.